Skip to main content

Catalyst Calendar

Scope
Catalyst

Wed, Aug 19, 2026

1 updates
MRK
6:45 AM

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma

First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran...

Trial Results • Phase 3presentation Wed, Aug 19, 2026, 6:45 AM EDTmerck.com

Tue, Jul 21, 2026

1 updates
MRK
10:22 AM

Investigational Once-weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy

– High Rates of Virologic Suppression Sustained at Week 48 Across ISL/LEN Treatment Groups in Both Phase 3 ISLEND Trials – – ISL/LEN has the Potential to be the First Once-Weekly Oral HIV Treatment – FOSTER CITY, CA, & RAHWAY, NJ, July 21, 2026 – Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE:...

Trial Results • Phase 3AIDS 2026 press program Tue, Jul 21, 2026, EDTmerck.com

Wed, Jul 15, 2026

2 updates
MRK
7:00 AM

Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026

Late-breaker presentations will highlight investigational, once-weekly oral combinations of islatravir with lenacapavir (Phase 3 ISL/LEN) and with ulonivirine (Phase 2b ISL+ULO) in adults with virologically-suppressed HIV-1 RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE:...

Presentation / Abstract • Phase 3AIDS 2026 oral presentation Tue, Jul 28, 2026, 10:30 AM BRTmerck.com
MRK
6:45 AM

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

KEYTRUDA is the first and only PD-1 inhibitor to improve PFS compared to platinum doublet chemotherapy for these patients in a Phase 3 trial RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Phase 3 KEYNOTE‑C93 trial evaluating KEYTRUDA ®...

Trial Results • Phase 3Results event Wed, Dec 31, 2025merck.com

Mon, Jun 22, 2026

1 updates
MRK
6:45 AM

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

Tulisokibart is the first anti-TL1A monoclonal antibody to demonstrate clinical remission at 12 weeks in moderately to severely active UC in a Phase 3 trial Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in inflammatory bowel disease (IBD) and other immune-mediated inflammatory conditions RAHWAY,...

Trial Results • Phase 3Results event Wed, Dec 31, 2025merck.com

Mon, Jun 8, 2026

2 updates
MRK
4:39 PM

Gilead and Merck Announce Positive Topline Results from two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

– Novel Investigational Combination Pairs Merck’s Islatravir, a Next-Generation Nucleoside Analog with Multiple Mechanisms of Action, including Translocation Inhibition, with Gilead’s Lenacapavir, a First-in-Class Capsid Inhibitor that Disrupts HIV at Multiple Stages of its Lifecycle – – Islatravir/Lenacapavir has the Potential to be the First Approved...

Trial Results • Phase 3Topline results Mon, Jun 8, 2026, 4:39 PM EDTmerck.com
MRK
4:30 PM

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

RAHWAY, N.J. & FOSTER CITY, Calif.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (Nasdaq: GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead’s Trodelvy ® (sacituzumab govitecan-hziy) in combination with KEYTRUDA ® (pembrolizumab),...

Trial Results • Phase 3Results event Wed, Dec 31, 2025merck.com

Mon, Jun 1, 2026

1 updates
MRK
8:00 AM

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA® (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared to KEYTRUDA alone Intismeran autogene in combination with KEYTRUDA...

Presentation / Abstract • Phase 2ASCO presentation Mon, Jun 1, 2026, 8:00 AM EDTmerck.com